Conditions: Progressive Cognitive Decline
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 239
Healthy volunteers: no

Brief summary:
The study is designed to evaluate whether a florbetapir F 18 PET scan can impact clinical thinking when physicians are determining the likely cause of a subject's cognitive impairment.

Detailed description:

Arms:
arm 1: Subjects who have previously or are currently being evaluated for progressive cognitive decline. Enrolling physicians must have a confidence of less than 85% in their initial diagnosis of the subject's progressive cognitive decline and that there was at least a 15% chance that the subject's progressive cognitive decline was due to Alzheimer's disease. All subjects who did not complete the study withdrew before receiving a florbetapir F 18 injection and PET scan.

Interventions: intervention 1: florbetapir F 18
Intervention descriptions: intervention 1: IV injection, 370 megabecquerel (MBq) (10 millicurie \[mCi\]), single dose

Protocol document: